BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GHZ339 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GHZ339\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06947993-1371@assetmemo.bio
DTSTAMP:20261121T005845Z
DTSTART;VALUE=DATE:20281127
DTEND;VALUE=DATE:20281128
SUMMARY:GHZ339: Phase 2 readout est. (NCT06947993)
DESCRIPTION:GHZ339\, phase 2\, Atopic Dermatitis.\nStudy: Platform Study to
  Evaluate the Efficacy and Safety of Investigational Compound(s) in Patien
 ts With Moderate to Severe Atopic Dermatitis\nEstimated primary completion
 : 27 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 hz339#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06947993
URL:https://assetmemo.bio/drug/ghz339#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
